Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 29
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
12/20/2006
 
First Published:
1/13/2006
1.
Phase III Randomized Study of Standard Chemoradiotherapy With Versus Without High-Dose Methotrexate in Pediatric Patients With Newly Diagnosed, Malignant High-Grade Glioma or Diffuse Intrinsic Pontine Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
3 to 18
Other
GPOH-HIT-GBM-D
EU-205100, NCT00278278
Last Modified:
6/11/2008
 
First Published:
10/21/2006
2.
Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 10 at diagnosis
Other
CHLA-HEAD-START-III
CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
Last Modified:
10/5/2007
 
First Published:
7/22/2005
3.
A Phase I/II Study of Erlotinib and Radiotherapy in Young Patients With Newly Diagnosed Intracranial High-Grade Glioma or Unfavorable Low-Grade Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
3 to 25
NCI, Pharmaceutical / Industry
SJCRH-SJHG04
GENENTECH-OSI3160s, NCT00124657
4.
A Phase I/II Study of the Photon Radiosurgery System
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
2 to 32
Other
CNS 0201
NCT00179907
5.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
1 to 120
Other
R01 CA 89395-01
Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
Last Modified:
12/7/2007
 
First Published:
11/1/1998
6.
Phase II Study of Antineoplastons A10 and AS2-1 in Children With Primary Malignant Brain Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
6 months to 17 years
Other
BC-BT-22
NCT00003476
Last Modified:
11/2/2007
 
First Published:
11/1/1998
7.
Phase II Study of Antineoplastons A10 and AS2-1 in Children With Recurrent or Refractory High-Grade Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
6 months to 17 years
Other
BC-BT-6
NCT00003535
Last Modified:
12/21/2007
 
First Published:
10/25/2004
8.
Phase II Study of Lapatinib in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Primitive Neuroectodermal Tumors, High-Grade Glioma, or Ependymoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
21 and under
NCI
PBTC-016
PBTC-016, NCT00095940
Last Modified:
5/9/2008
 
First Published:
7/23/2006
9.
Phase II Pilot Study of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Young Patients With Relapsed or Progressive Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
21 and under
Other
DFCI-04343
NCT00357500
Last Modified:
10/9/2008
 
First Published:
9/23/2006
10.
Phase II Study of Bevacizumab and Irinotecan Hydrochloride in Pediatric Patients With Recurrent, Progressive, or Refractory Malignant Glioma, Diffuse or Intrinsic Brain Stem Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Diagnostic, Treatment
Active
21 and under
NCI
PBTC-022
PBTC-022, NCT00381797
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute